Lillyroussopoker.US) fell 3% to 733roussopoker.27 dollars. on the news frontroussopokerAmgen's mid-term trial of a new weight-loss drug receives positive data. If the drug is approved, it will compete with Novo NordiskroussopokerWegovy and Lilly's Zepbound compete.
Earlier, some media said that Amgen is trying a new weight-loss drug, whose mechanism of action is different from Novo Nordisk and Lilly products, which can prevent patients from gaining weight even if they stop taking the drug.
转载声明：本站发布文章及版权归原作者所有，转载本站文章请注明文章来源！